Key Takeaways

Growing adoption of genetic testing, payer acceptance, and expanded infusion networks are driving revenue growth, pricing power, and increased patient access to therapies.
Pipeline expansion, external collaborations, and manufacturing scale are positioning the company for diversified growth, improved margins, and long-term earnings gains.
Heavy reliance on a single therapy, regulatory scrutiny, pricing and access pressures, and high costs threaten revenue growth and long-term profitability.

Catalysts

About Sarepta Therapeutics

A commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.What are the underlying business or industry changes driving this perspective?

The broadening adoption of genetic testing and precision medicine is expanding the potential patient pool for Sarepta’s therapies, particularly ELEVIDYS and future gene therapies, enabling higher long-term revenue growth by accelerating early diagnosis and increasing the number of eligible patients.
Enhanced payer acceptance and robust access, as evidenced by a 100% current success rate for obtaining ELEVIDYS insurance coverage, combined with global healthcare systems’ willingness to reimburse for high-value gene therapies, support sustained pricing power and revenue expansion for Sarepta’s portfolio.
The continued scaling and operational optimization of infusion centers—moving beyond overburdened top thought leader sites to a broader network of secondary sites—will unlock significant site capacity, enabling Sarepta to accelerate patient throughput and drive inflection points in quarterly and annual revenue.
Advancing the company’s gene therapy platform into new indications, such as multiple subtypes of limb-girdle muscular dystrophy (LGMD), and near-term catalysts including a BLA filing for EMERGENE and data from additional siRNA programs, set the stage for revenue diversification and multi-year top-line growth.
Sarepta’s increased pipeline velocity, strengthened by external collaborations (such as the Arrowhead partnership), maturing manufacturing scale, and prudent capital allocation, positions the company to improve operating leverage, potentially expand net margins, and support long-term earnings growth as new therapies are commercialized globally.

Sarepta Therapeutics Earnings and Revenue Growth

Sarepta Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more optimistic perspective on Sarepta Therapeutics compared to the consensus, based on a Fair Value that aligns with the bullish cohort of analysts.
The bullish analysts are assuming Sarepta Therapeutics's revenue will decrease by 9.0% annually over the next 3 years.
The bullish analysts assume that profit margins will increase from -2.3% today to 36.7% in 3 years time.
The bullish analysts expect earnings to reach $686.8 million (and earnings per share of $5.65) by about August 2028, up from $-58.0 million today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the price target of the more bullish analyst cohort, the company would need to trade at a PE ratio of 10.8x on those 2028 earnings, up from -34.2x today. This future PE is lower than the current PE for the US Biotechs industry at 15.4x.
Analysts expect the number of shares outstanding to grow by 2.46% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.73%, as per the Simply Wall St company report.

Sarepta Therapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Sarepta’s narrow focus on Duchenne muscular dystrophy and its heavy reliance on ELEVIDYS exposes the company to significant revenue risk if competitive therapies, new standards of care, or disruptive gene-editing technologies emerge, which could erode its flagship product revenue and reduce long-term revenue growth.
Rising scrutiny of gene therapy safety following the recent ELEVIDYS-related patient death, along with costly, complex regulatory and administrative processes, heightens the risk of delayed approvals, label restrictions, or setbacks in patient uptake, putting pressure on both future revenue and gross margins.
Increasing pricing pressures from payers and political momentum toward stricter pharmaceutical price regulations in the US and Europe may hamper Sarepta’s ability to command premium prices for its high-cost therapies, compressing net margins and curbing earnings growth over time.
Persistently high R&D and manufacturing expenses for gene therapies, exemplified by large upfront payments such as the $584 million Arrowhead collaboration, risk driving prolonged operating losses if commercialization does not accelerate or costs continue to escalate, which could negatively impact earnings and free cash flow.
Economic barriers for patients with rare diseases and uncertainty around broad insurance coverage could shrink Sarepta’s addressable market by limiting access to its therapies, undermining potential sales growth, and ultimately impacting long-term revenue expansion and profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bullish price target for Sarepta Therapeutics is $56.26, which represents two standard deviations above the consensus price target of $23.52. This valuation is based on what can be assumed as the expectations of Sarepta Therapeutics's future earnings growth, profit margins and other risk factors from analysts on the bullish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $80.0, and the most bearish reporting a price target of just $5.0.
In order for you to agree with the bullish analysts, you'd need to believe that by 2028, revenues will be $1.9 billion, earnings will come to $686.8 million, and it would be trading on a PE ratio of 10.8x, assuming you use a discount rate of 7.7%.
Given the current share price of $20.3, the bullish analyst price target of $56.26 is 63.9% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Rising Genetic Testing And Precision Medicine Will Unlock New Markets

Shared on07 May 25Fair value Decreased 73%

Shared on30 Apr 25

Shared on23 Apr 25Fair value Increased 103%

Shared on07 May 25
Fair value Decreased 73%

Shared on23 Apr 25
Fair value Increased 103%